InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,992.61
(
0.16%
)
Post# of 21373
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Rat Fink

Send PM Follow Ignore
Followers 292
Posts 76099
Boards Moderated 3
Alias Born 03/20/2013

Rat Fink

Member Level

Re: A deleted message

Monday, 03/19/2018 9:41:24 PM

Monday, March 19, 2018 9:41:24 PM

Post# of 21373
CHECK OUT M.D. ANDERSON'S PRE-CLINICAL_TRIAL_INFO_ON_PROLANTA/G129R!!!_http://nebula.wsimg.com/5542c0afba149bcb25b0b56a5099a065?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

Conclusion (lower left-hand corner): G129R functions as a molecular
antagonist to tumor-associated PRL by inducing
adaptive autophagic cell death in human ovarian cancer.
These preclinical findings reveal the novelty of G129R as
an adjuvant therapy for ovarian cancer

CONCLUSIONS (LOWER RIGHT-HAND CORNER)
1. Prolactin antagonist, G129R, inhibits ovarian cancer growth and
progression;
2. PRLR is required for G129R induced autophagy;
3. PEA-15 mediates autophagic cell death induced by blocking
PLR/PRLR signaling;

Prolanta™ (referenced in the scientific literature as G129R): https://www.oncolixbio.com/prolanta-structure.html

Prolanta: https://www.oncolixbio.com/home.html

"The stock market is a device for transferring money from the impatient to the patient" — Warren Buffett

"The Big Money is not in the buying and the selling but in the waiting" — Charlie Munger

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up